Cargando…
Gemcitabine-associated thrombotic microangiopathy in a patient with lung cancer: A case report
Gemcitabine is frequently used for the treatment of a number of different cancer types. Gemcitabine-related thrombotic microangiopathy (TMA) has rarely been described, but it is a life-threatening complication. The incidence of the complication varies between 0.015 and 1.4%. The present study report...
Autores principales: | Lai-Tiong, Florence, Duval, Yann, Krabansky, Francois |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403528/ https://www.ncbi.nlm.nih.gov/pubmed/28454234 http://dx.doi.org/10.3892/ol.2017.5576 |
Ejemplares similares
-
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre
por: Grall, Maximilien, et al.
Publicado: (2021) -
Thrombotic Microangiopathy Associated with Gemcitabine in Non-Small Cell Lung Cancer: A Case Report
por: Kuribayashi, Tadahiro, et al.
Publicado: (2021) -
A rare case report of gemcitabine-induced thrombotic
microangiopathies
por: Madkhali, Mohammed Ali
Publicado: (2021) -
Gemcitabine-Induced Renal Thrombotic Microangiopathy
por: Chaudhary, Ankur, et al.
Publicado: (2023) -
Gemcitabine-induced thrombotic microangiopathy treated with eculizumab: a case report
por: Van den Eeckhaut, Lisa, et al.
Publicado: (2022)